Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab for Hospitalized Patients With COVID-19
NCT04315298Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2020
- Primary completion
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sarilumab in coronavirus disease 2019 (COVID-19), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Percent Change From Baseline in CRP Levels at Day 4 and Percentage of Participants With at Least a 1-point Improvement in Clinical Status at Day 22. Started Mar 2020; status: completed.
02
Drugs
sarilumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04315298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04315298.